In the second half of the year, the deputy general managers of more than 7 pharmaceutical companies changed!

[Pharmaceutical Network Industry News] The pharmaceutical market is surging, and executives are changing more frequently, many of whom are highly concerned about the positions of deputy general manager.
Since the second half of this year, in less than two months, there have been news of the change of deputy general managers of seven pharmaceutical companies including Harbin Pharmaceutical, Si Litai, China Pharmaceutical, ST Yikang, Xingqi Eye Medicine, and Sinopharm Grou.
Most of the reasons are mainly personal reasons, in addition to work adjustment, retirement and so o.
On August 11, *ST Yikang announced that M.
Yan Xiaojia, the company's deputy general manager and secretary of the board of directors, applied for his resignation due to personal reason.
After his resignation, M.
Yan Xiaojia will not hold other positions in the compan.
On August 10, Harbin Pharmaceutical announced that the company's board of directors recently received a written resignation report submitted by the company's deputy general manager, M.
Xiao Qian.
Due to personal reasons, M.
Xiao Qiang resigned from the position of Deputy General Manager of the Company and no longer holds any other positions in the Company after his resignatio.
On August 3, Si Litai announced that M.
Fang Qinhu, the deputy general manager of the company, applied to resign from the position of deputy general manager of the company due to personal reason.
After resigning, M.
Fang Qinhu no longer held any positions in the compan.
On July 29, Sinopharm announced the resignation of many senior executive.
Among them, M.
Yuan Yingsheng and M.
Chen Jing respectively applied to resign as deputy general managers of the company due to job adjustmen.
M.
Yuan Yingsheng will no longer hold any positions in the company, and M.
Chen Jing will continue to serve as research manager in the compan.
On July 28, Sinopharm Group announced that M.
Wu Jie, the company's deputy general manager, has retired and no longer holds any positions as the company's deputy general manager and subsidiarie.
On July 2, Xinmai Medical announced that the company's board of directors recently received the resignation report of M.
Jin Guocheng, the company's deputy general manage.

M.
Jin Guocheng applied for his resignation as deputy general manager of the company due to personal reason.
After his resignation, M.
Jin Guocheng will no longer hold any positions in the compan.
However, there are executives who "leave" and those who take offic.
For example, Xingqi Eye Medicine announced on July 18 that M.
Liu Jidong decided to resign as the general manager of the company after careful consideratio.
The board of directors agreed to appoint M.
Gao E as the general manager of the compan.
Manager jo.
On the same day, the board of directors agreed to appoint M.
Yang Qiang as the deputy general manager of the compan.
The deputy general manager of a pharmaceutical company plays an important role in the enterprise and is the general manager's staff and assistan.
He needs to assist the general manager to formulate and implement the company's overall strategy and annual business plan, complete the responsibility goals and annual plans, and establish and improve the company's management system and organizational structure,et.
Behind the resignation of a large number of deputy general managers of pharmaceutical companies, it can be seen that the adjustment of the pharmaceutical industry is acceleratin.
The industry believes that under the background of centralized procurement, consistency evaluation, and medical insurance cost control, traditional pharmaceutical companies may face problems such as insufficient growth momentum, great transformation challenges, et.
, and the difficulty of executive decision-making has also greatly increase.
Traditional pharmaceutical companies will definitely be more difficult, executives will be more aware of the difficulties in the future, and their exodus will be accelerate.
” In less than two months, the deputy general managers of at least 7 pharmaceutical companies have changed, which shows a new round of pharmaceutical industry talent.
The changes are accelerating, and the next step may be accompanied by more adjustments in the internal business of pharmaceutical companie.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.